|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (5Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
Moody's Investors Service ("Moody's") today assigned Ba1 ratings to the senior unsecured notes to be offered by Becton Dickinson Euro Finance S.a.r.l. As part of the refinancing, BD plans to repay at maturity its euro 1 billion notes due in June 2019 and to tender for certain other outstanding notes of BD.
Moody's Investors Service ("Moody's") today affirmed all of Becton, Dickinson & Company's ("BD") ratings including the Ba1 Corporate Family Rating, Ba1-PD Probability of Default Rating, Not Prime commercial paper rating, SGL-1 Speculative Grade Liquidity rating and the Ba1 senior unsecured rating. "The revision in the outlook to positive considers the deleveraging progress that BD has made since the closing of the Bard acquisition in December 2017" said Moody's Senior Vice President Scott Tuhy.
The outlook for the US medical products and devices industry has been revised upward, to positive from stable, Moody's Investors Service says in a just-published report. Continued product innovation and ...
Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.